VanEck Pharmaceutical ETF
PPH
58 hedge funds and large institutions have $141M invested in VanEck Pharmaceutical ETF in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 9 closing their positions.
0% more funds holding
Funds holding: 58 → 58 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
5.05% less ownership
Funds ownership: 45.74% → 40.69% (-5.1%)
9% less capital invested
Capital invested by funds: $155M → $141M (-$13.7M)
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFM
Lumina Fund Management
New York
|
+$3.75M |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$2.06M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.82M |
| 4 |
WIC
Woodmont Investment Counsel
Nashville,
Tennessee
|
+$1.25M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$12.5M |
| 2 |
Morgan Stanley
New York
|
-$8.32M |
| 3 |
VF
Virtu Financial
New York
|
-$4.35M |
| 4 |
LPL Financial
San Diego,
California
|
-$870K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$709K |
PPH Hedge Fund Activity: Q2 2016 in Review
58 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2016, worth a combined $141M — down 8.9% from $155M a quarter earlier.
Fund positioning in PPH was balanced in Q2 2016: 9 funds opened new positions, 9 closed out, 13 added to existing stakes and 23 trimmed.
The largest buyer was Lumina Fund Management, opening a new position worth an estimated $3.75M. The largest seller was Harel Insurance Investments & Financial Services, cutting an estimated $12.5M.
- 58 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $141M of VanEck Pharmaceutical ETF stock for Q2 2016, down 8.9% quarter-over-quarter.
- 9 funds opened new VanEck Pharmaceutical ETF positions in Q2 2016 and 9 closed out, a net change of 0 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2016 was Lumina Fund Management, an estimated $3.75M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2016 was Harel Insurance Investments & Financial Services, an estimated $12.5M sold.
Based on aggregated 13F filings for Q2 2016.